Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study

Karel Pavelka, Z. Szekanecz, Nemanja Damjanov, Maria Majdan, Evgeny Nasonov, Vadim Mazurov, Tibor Fabo, Eustratios Bananis, Heather Jones, Annette Szumski, Boxiong Tang, Sameer Kotak, Andrew S. Koenig, Radu Vasilescu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Biologics have mainly been assessed in patients with severe rheumatoid arthritis (RA) globally. Less attention has been paid to moderately active disease, especially in Central and Eastern Europe (CEE). Access to biologics and the disease features of RA patients may differ in CEE, relative to other regions. We assessed the clinical and patient-reported outcomes (PROs) of treatment from CEE patients in the multinational PRESERVE study (NCT00565409). Patients with moderate RA 28-joint disease activity score ((DAS28) erythrocyte sedimentation rate (ESR) >3.2 and ≤5.1) despite methotrexate (MTX) treatment received open-label etanercept (ETN) 50 mg QW + MTX for 36 weeks. Low disease activity (DAS28 low disease activity (LDA) ≤3.2) and remission (DAS28 ESR

Original languageEnglish
Pages (from-to)1275-1281
Number of pages7
JournalClinical Rheumatology
Volume32
Issue number9
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Eastern Europe
Methotrexate
Rheumatoid Arthritis
Blood Sedimentation
Biological Products
Joint Diseases
Therapeutics
Etanercept

Keywords

  • (4 to 6) Rheumatoid arthritis
  • Central Europe
  • Eastern Europe
  • Etanercept
  • Methotrexate

ASJC Scopus subject areas

  • Rheumatology

Cite this

Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. / Pavelka, Karel; Szekanecz, Z.; Damjanov, Nemanja; Majdan, Maria; Nasonov, Evgeny; Mazurov, Vadim; Fabo, Tibor; Bananis, Eustratios; Jones, Heather; Szumski, Annette; Tang, Boxiong; Kotak, Sameer; Koenig, Andrew S.; Vasilescu, Radu.

In: Clinical Rheumatology, Vol. 32, No. 9, 09.2013, p. 1275-1281.

Research output: Contribution to journalArticle

Pavelka, K, Szekanecz, Z, Damjanov, N, Majdan, M, Nasonov, E, Mazurov, V, Fabo, T, Bananis, E, Jones, H, Szumski, A, Tang, B, Kotak, S, Koenig, AS & Vasilescu, R 2013, 'Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study', Clinical Rheumatology, vol. 32, no. 9, pp. 1275-1281. https://doi.org/10.1007/s10067-013-2240-4
Pavelka, Karel ; Szekanecz, Z. ; Damjanov, Nemanja ; Majdan, Maria ; Nasonov, Evgeny ; Mazurov, Vadim ; Fabo, Tibor ; Bananis, Eustratios ; Jones, Heather ; Szumski, Annette ; Tang, Boxiong ; Kotak, Sameer ; Koenig, Andrew S. ; Vasilescu, Radu. / Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. In: Clinical Rheumatology. 2013 ; Vol. 32, No. 9. pp. 1275-1281.
@article{f8c662771e254a0bbb6133fce0be7891,
title = "Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study",
abstract = "Biologics have mainly been assessed in patients with severe rheumatoid arthritis (RA) globally. Less attention has been paid to moderately active disease, especially in Central and Eastern Europe (CEE). Access to biologics and the disease features of RA patients may differ in CEE, relative to other regions. We assessed the clinical and patient-reported outcomes (PROs) of treatment from CEE patients in the multinational PRESERVE study (NCT00565409). Patients with moderate RA 28-joint disease activity score ((DAS28) erythrocyte sedimentation rate (ESR) >3.2 and ≤5.1) despite methotrexate (MTX) treatment received open-label etanercept (ETN) 50 mg QW + MTX for 36 weeks. Low disease activity (DAS28 low disease activity (LDA) ≤3.2) and remission (DAS28 ESR",
keywords = "(4 to 6) Rheumatoid arthritis, Central Europe, Eastern Europe, Etanercept, Methotrexate",
author = "Karel Pavelka and Z. Szekanecz and Nemanja Damjanov and Maria Majdan and Evgeny Nasonov and Vadim Mazurov and Tibor Fabo and Eustratios Bananis and Heather Jones and Annette Szumski and Boxiong Tang and Sameer Kotak and Koenig, {Andrew S.} and Radu Vasilescu",
year = "2013",
month = "9",
doi = "10.1007/s10067-013-2240-4",
language = "English",
volume = "32",
pages = "1275--1281",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "9",

}

TY - JOUR

T1 - Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study

AU - Pavelka, Karel

AU - Szekanecz, Z.

AU - Damjanov, Nemanja

AU - Majdan, Maria

AU - Nasonov, Evgeny

AU - Mazurov, Vadim

AU - Fabo, Tibor

AU - Bananis, Eustratios

AU - Jones, Heather

AU - Szumski, Annette

AU - Tang, Boxiong

AU - Kotak, Sameer

AU - Koenig, Andrew S.

AU - Vasilescu, Radu

PY - 2013/9

Y1 - 2013/9

N2 - Biologics have mainly been assessed in patients with severe rheumatoid arthritis (RA) globally. Less attention has been paid to moderately active disease, especially in Central and Eastern Europe (CEE). Access to biologics and the disease features of RA patients may differ in CEE, relative to other regions. We assessed the clinical and patient-reported outcomes (PROs) of treatment from CEE patients in the multinational PRESERVE study (NCT00565409). Patients with moderate RA 28-joint disease activity score ((DAS28) erythrocyte sedimentation rate (ESR) >3.2 and ≤5.1) despite methotrexate (MTX) treatment received open-label etanercept (ETN) 50 mg QW + MTX for 36 weeks. Low disease activity (DAS28 low disease activity (LDA) ≤3.2) and remission (DAS28 ESR

AB - Biologics have mainly been assessed in patients with severe rheumatoid arthritis (RA) globally. Less attention has been paid to moderately active disease, especially in Central and Eastern Europe (CEE). Access to biologics and the disease features of RA patients may differ in CEE, relative to other regions. We assessed the clinical and patient-reported outcomes (PROs) of treatment from CEE patients in the multinational PRESERVE study (NCT00565409). Patients with moderate RA 28-joint disease activity score ((DAS28) erythrocyte sedimentation rate (ESR) >3.2 and ≤5.1) despite methotrexate (MTX) treatment received open-label etanercept (ETN) 50 mg QW + MTX for 36 weeks. Low disease activity (DAS28 low disease activity (LDA) ≤3.2) and remission (DAS28 ESR

KW - (4 to 6) Rheumatoid arthritis

KW - Central Europe

KW - Eastern Europe

KW - Etanercept

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=84883252200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883252200&partnerID=8YFLogxK

U2 - 10.1007/s10067-013-2240-4

DO - 10.1007/s10067-013-2240-4

M3 - Article

C2 - 23666316

AN - SCOPUS:84883252200

VL - 32

SP - 1275

EP - 1281

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 9

ER -